Strategic Consulting and Advisory Services
Certara is the largest and most comprehensive provider of biosimulation (modeling and simulation), strategic pharmacometrics, and regulatory writing consulting services. Our multidisciplinary team works alongside clients to inform key drug development decisions and expedite the processes around achieving regulatory milestones.
Software Portfolio: 'End-to-end' Modeling
Certara biosimulation (model based drug development and informatics) software portfolio is the most wide-ranging in the industry. Certara technology is relied upon by over 1,500 biopharm companies and academic institutions for drug research and development.
Certara's Programmatic Consulting Approach Delivers Unquestionable Value to Sponsor Companies
Certara combines its industry renowned pharmacometric and regulatory consultants with our vast software portfolio to provide services that focus on specific outcomes, therapeutic areas, regulatory milestones, and specific populations.
Leading Edge Science: Resource Library
Check out the latest brochures, case studies, white papers, webinars, and more! Search by keywords and/or filter results.
Certara Pharmacometrician Receives Faculty Appointment at University of Montreal
August 27, 2015
PRINCETON, NJ – Aug. 27, 2015 – Certara®, the global biosimulation technology-enabled drug development company, today announced that its Director of Pharmacometrics Samer Mouksassi, PharmD, PhD, FCP, has been appointed an associate professor in the Faculty of Pharmacy at the University of Montreal. In this new role, Dr. Mouksassi will teach clinicians and students how biosimulation can be used to improve drug development and enhance health outcomes.
“Samer is a very smart, dedicated scientist who thoroughly enjoys sharing his technical knowledge and vision with his peers,” said Certara Chief Executive Officer Edmundo Muniz, MD, PhD. “I am confident that he will inspire his students to explore new ways of using biosimulation to help bring safer, more effective therapies to the patients who need them.”
“I strongly believe that establishing partnerships between industry and academia is the best way to advance science,” said Dr. Mouksassi. “This is a wonderful opportunity to be able to speak to fellow pharmacists and demonstrate how biosimulation can enhance our work. I am delighted to play this dual role at my alma mater.”
Dr. Mouksassi started his career as a clinical pharmacist in a research hospital where he led efforts to start a therapeutic drug monitoring service using Bayesian feedback. He developed population pharmacokinetic/pharmacodynamic models to help clinicians select the best drug doses for patients; his primary focus was on pediatrics.
He joined Certara’s Pharsight Consulting Services (PCS) in 2007 and has helped its biopharm clients to apply model-based drug development to more than 100 studies. These contributions have generated more than 60 pharmacometrics papers in peer-reviewed journals in a wide range of therapeutic areas. In July 2015, PCS was merged with Quantitative Solutions, a Menlo Park, CA-based global pharmacometrics consulting company, and became Certara Strategic Consulting.
Dr. Mouksassi earned his PhD in Pharmaceutical Sciences from the University of Montreal, Faculty of Pharmacy and his PharmD from Lebanese University. He is also a fellow of the American College of Clinical Pharmacology.
About Certara
Certara is a global biosimulation technology-enabled drug development company. Its customers include hundreds of biopharmaceutical companies around the globe, together with several regulatory agencies. Certara’s solutions, which span the discovery, preclinical and clinical stages of drug development, enable superior drug development and regulatory decision-making through biosimulation, thus increasing R&D productivity and commercial value. For more information, visit www.certara.com.
Certara Contact:
Ellen Leinfuss, 609-216-9586
Chief Marketing Officer
Media Contact:
Lisa Osborne, 206-992-5245
Rana Healthcare Solutions
lisa@ranahealth.com